Navigation Links
Osteoporosis Meds Linked to Heart Problem
Date:10/27/2008

Bisphosphonates may up rate of serious atrial fibrillation, review finds,,,,

MONDAY, Oct. 27 (HealthDay News) -- The popular bone-building medications known as bisphosphonates may have a rare, but serious, cardiac side effect.

A review of available research concludes that these medications may increase the risk of atrial fibrillation -- an erratic heart rhythm that can lead to blood clots that may cause heart attacks or strokes.

"In addition to possible gastrointestinal side effects, bisphosphonates can have possible cardiac side effects. For serious cases of atrial fibrillation, there was a significant increase in risk -- about 68 percent," said review lead author Dr. Jennifer Miranda, an internal medicine resident at Jackson Memorial Hospital in Miami.

But Miranda noted that the absolute risk of someone experiencing atrial fibrillation while on these medications was actually quite small, probably around 1 percent to 2 percent.

Miranda was expected to present the findings Monday at the American College of Chest Physicians annual meeting, in Philadelphia.

Bisphosphonates are a class of medications that increase bone mineral density. They are commonly prescribed to treat people with osteoporosis and also for people who have suffered hip fractures. Bisphosphonates may also be used to treat Paget's disease of bone.

This class of medications includes alendronate (Fosamax), zoledronic acid (Reclast), ibandronate (Boniva), risedronate (Actonel), and more.

Although effective, these medications can cause serious side effects in some people. Gastrointestinal side effects, such as nausea, stomach pain, constipation and diarrhea can occur. Of more concern are rare side effects, such as osteonecrosis of the jaw, unusual bone fractures, and severe muscle, bone or joint pain.

The U.S. Food and Drug Administration is reviewing the safety of bisphosphonates, but at this time doesn't recommend any changes in clinical practice.

Miranda's review focused on three studies of bisphosphonates that included data on atrial fibrillation as a side effect. Miranda said the authors reviewed 1,646 studies, but only three included information on atrial fibrillation.

All three studies were randomized, placebo-controlled studies published in the New England Journal of Medicine in 2007, and included more than 16,000 patients. The study populations were quite similar and included postmenopausal women between the ages of 69 and 75 who were taking bisphosphonates for osteoporosis.

The overall difference in incidence of atrial fibrillation wasn't statistically significant between those taking bisphosphonates and placebo. However, when the researchers looked just at serious atrial fibrillation, meaning that it was significant enough to require hospitalization or caused death, they found a 68 percent increased risk for those on bisphosphonates.

Miranda said it's not clear why bisphosphonates might increase the risk of atrial fibrillation.

Dr. Arthur Santora, executive director of clinical research at Merck Research Laboratories, said he was surprised that the current analysis only included three studies. Generally, he said, this type of research will include a dozen or more studies. Merck manufactures Fosamax.

Santora said his researchers have also done a meta-analysis to look at atrial fibrillation, but they included 40 studies, and they didn't find an increase in the risk of serious atrial fibrillation.

"Although this is something you want to track, and we do carefully track atrial fibrillation, there doesn't appear to be an increased risk when you look at the 40 studies we included in our meta-analysis," said Santora.

Santora said that if patients have any concerns about potential side effects, they should talk to their physicians about those concerns.

More information

Here's the latest from the U.S. Food and Drug Administration on bisphosphonates and atrial fibrillation.



SOURCES: Jennifer Miranda, M.D., internal medicine resident, Jackson Memorial Hospital, Miami; Arthur Santora, M.D., executive director, clinical research, Merck Research Laboratories, Whitehouse Station, N.J.; Oct. 27, 2008, presentation, American College of Chest Physicians annual meeting, Philadelphia


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Vitamin D Added to FDA Osteoporosis Risk-Reduction Health Claim
2. Retrospective study analyzes expenses of osteoporosis-related fracture over 3 years
3. Simple ultrasound exam may predict osteoporosis risk
4. Figure Skater Peggy Fleming Teams With HealthSaver: Osteoporosis and Bone Health
5. Tufts researcher leads revision of osteoporosis guidelines
6. New study shows sedentary high school girls are at significant risk for future osteoporosis
7. Global study reveals differences in standard of care for osteoporosis across the world
8. National Osteoporosis Foundation Survey Reveals Low Awareness of Bone Health and Risk of Osteoporosis
9. Treating osteoporosis calls for physician, dentist collaboration: ADA Journal
10. Docs Issue Guideline on Screening for Osteoporosis in Men
11. Genes Linked to Osteoporosis Identified
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Osteoporosis Meds Linked to Heart Problem
(Date:10/13/2017)... ... ... While it’s often important to take certain medications during the night, finding ... identified a solution. , She developed a prototype for MOTION LIGHT-UP PILL BOX to ... the need to turn on a light when taking medication during the night, allowing ...
(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a leading ... Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil will revolutionize the rapidly ... CBD form that can be easily incorporated into liquid products, while reducing costs to ...
(Date:10/13/2017)... Shelton, CT (PRWEB) , ... October 13, 2017 , ... ... and long-term care services, staged a mock evacuation of the facility as part of ... Department, Shelton Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network ... advocate for action towards gender equality at their inaugural Summit in New York City ... and reached a social audience of over 3 million. To watch the Mobilize Women ...
(Date:10/13/2017)... ... 13, 2017 , ... Talented host, actor Rob Lowe, is ... a new episode of "Success Files," which is an award-winning educational program broadcasted ... each subject in-depth with passion and integrity. , Sciatica occurs when the sciatic ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... Halo Labs announces the European launch of their new ... at MIBio 2017 in Cambridge, U.K on ... in biopharmaceutical samples with unprecedented speed and sensitivity while using far ... Membrane Imaging. ... particle analysis system ...
(Date:9/27/2017)... , Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), a leading ... announced that its MyDario product is expected to appear on The Dr. ... The Dr. Oz Show airs in your area: http://www.doctoroz.com/page/where-watch-dr-oz-show ... The nine-time Emmy award-winning, The Dr. Oz Show ... The segment ...
(Date:9/22/2017)... , Sept. 22, 2017 AVACEN Medical ... device is now successfully helping those with the widespread ... Fibromyalgia diagnosed Amanda in Essex, England ... and washing my hair, experiencing no sleep at all, ... painful spasm… I cannot recommend [the AVACEN 100] enough, ...
Breaking Medicine Technology: